Delayed
Nasdaq Stockholm
08:53:06 2024-05-02 am EDT
|
5-day change
|
1st Jan Change
|
0.544
SEK
|
-2.86%
|
|
-1.09%
|
+19.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
326.8
|
274.5
|
275.5
|
254.8
|
165.1
|
202.6
|
-
|
-
|
Enterprise Value (EV)
1 |
326.8
|
274.5
|
223.1
|
254.8
|
128.9
|
202.6
|
202.6
|
202.6
|
P/E ratio
|
-9.38
x
|
-8.59
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
41
x
|
-
|
-
|
-
|
-
|
5.69
x
|
7.23
x
|
EV / Revenue
|
-
|
41
x
|
-
|
-
|
-
|
-
|
5.69
x
|
7.23
x
|
EV / EBITDA
|
-
|
-8.85
x
|
-5.68
x
|
-4.52
x
|
-3.69
x
|
-4.71
x
|
-13.2
x
|
-96.5
x
|
EV / FCF
|
-
|
-8,524,750
x
|
-5,963,554
x
|
-4,650,020
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
145,236
|
145,236
|
217,972
|
264,887
|
361,739
|
361,739
|
-
|
-
|
Reference price
2 |
2.250
|
1.890
|
1.264
|
0.9620
|
0.4565
|
0.5600
|
0.5600
|
0.5600
|
Announcement Date
|
2/6/20
|
2/11/21
|
3/25/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
6.7
|
-
|
-
|
-
|
-
|
35.6
|
28
|
EBITDA
1 |
-
|
-31
|
-48.5
|
-56.4
|
-44.8
|
-43
|
-15.4
|
-2.1
|
EBIT
1 |
-
|
-32.3
|
-49.8
|
-57.9
|
-46.5
|
-43
|
-15.4
|
-2.1
|
Operating Margin
|
-
|
-482.09%
|
-
|
-
|
-
|
-
|
-43.26%
|
-7.5%
|
Earnings before Tax (EBT)
1 |
-
|
-32.2
|
-49.8
|
-
|
-45.8
|
-43
|
-15.4
|
-2.1
|
Net income
1 |
-34.1
|
-32.2
|
-49.8
|
-58.4
|
-45.8
|
-43
|
-15.4
|
-2.1
|
Net margin
|
-
|
-480.6%
|
-
|
-
|
-
|
-
|
-43.26%
|
-7.5%
|
EPS
|
-0.2400
|
-0.2200
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-32.2
|
-46.2
|
-54.8
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-480.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
2/11/21
|
3/25/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
52.4
|
-
|
36.2
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-32.2
|
-46.2
|
-54.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-145%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
2/11/21
|
3/25/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +19.17% | 18.46M | | -1.17% | 104B | | +2.87% | 97.47B | | +5.01% | 22.25B | | -14.77% | 21.68B | | -8.63% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|